Datasheet for ABIN7566427

anti-IFIH1 antibody

Go to Product page

Overview

Quantity:	100 µg
Target:	IFIH1
Reactivity:	Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This IFIH1 antibody is un-conjugated
Application:	Western Blotting (WB), Immunohistochemistry (IHC)

Product Details

Purpose:	anti-MDA5 (mouse), pAb (AL180)
Immunogen:	Recombinant mouse MDA5 (aa 2-208).
Characteristics:	Polyclonal Antibody. Recognizes mouse MDA5. Source: Rabbit. Applications: IHC, WB. Liquid. In PBS containing 0.02 % sodium azide. RIG-I and MDA5 are highly conserved helicases involved in the innate immune response to virus. MDA5, upon interaction with intracellular dsRNA (produced during viral replication), triggers a transduction cascade involving MAVS/IPS1, which results in the activation of NF-kappaB, IRF3 and IRF7 and the induction of the expression of antiviral cytokines such as IFN-beta and RANTES (CCL5). MDA5 is widely expressed at low levels. The expression is detected at higher levels in placenta, pancreas and spleen and barely in brain, testis and lung. Genetic variation in MDA5 is associated with diabetes mellitus insulin-dependent type 19 (IDDM19). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. RIG-I and MDA5 are highly conserved helicases involved in the innate immune response to

Product Details

	virus. MDA5, upon interaction with intracellular dsRNA (produced during viral replication), triggers a transduction cascade involving MAVS/IPS1, which results in the activation of NF-kappaB, IRF3 and IRF7 and the induction of the expression of antiviral cytokines such as IFN-beta and RANTES (CCL5). MDA5 is widely expressed at low levels. The expression is detected at higher levels in placenta, pancreas and spleen and barely in brain, testis and lung. Genetic variation in MDA5 is associated with diabetes mellitus insulin-dependent type 19 (IDDM19). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy.
Purification:	Puified
Purity:	>95 % (SDS-PAGE)

Target Details

Target:	IFIH1
Alternative Name:	MDA5 (IFIH1 Products)
UniProt:	Q8R5F7
Pathways:	Activation of Innate immune Response

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	In PBS containing 0.02 % sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Avoid freeze/thaw cycles.
Storage:	4 °C,-20 °C

Handling

Storage Comment:	+4°C Stable for at least 1 year after receipt when stored at -20°C.